Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.

J Immunother Cancer 2018 12 4;6(1):137. Epub 2018 Dec 4.

Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.

Chimeric Antigen Receptor (CAR) T cell therapies - adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals. Based on the promise generated from these successes, the field is rapidly evolving to include new disease indications and CAR designs, while simultaneously reviewing and optimizing toxicity and management protocols. As such, this review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class.

Download full-text PDF

Source
https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0
Publisher Site
http://dx.doi.org/10.1186/s40425-018-0460-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278156PMC
December 2018
12 Reads

Publication Analysis

Top Keywords

cell therapies
12
hematologic malignancies
8
perspective significance
8
receptor car
8
car cell
8
chimeric antigen
8
antigen receptor
8
include disease
4
evolving include
4
disease indications
4
designs simultaneously
4
rapidly evolving
4
car designs
4
indications car
4
successes field
4
drug administration
4
food drug
4
three food
4
leading three
4
administration approvals
4

Altmetric Statistics

References

(Supplied by CrossRef)

K Perica et al.
Rambam Maimonides Med J 2015

L Baggio et al.
Clin Immunol 2017

S Anguille et al.
Lancet Oncol 2014

SA Rosenberg et al.
N Engl J Med 1988

X Tang et al.
PLoS One 2013

PW Kantoff et al.
N Engl J Med 2010

C Zhang et al.
Biomark Res 2017

G Gross et al.
Proc Natl Acad Sci U S A 1989

CL Bonifant et al.
Mol Ther Oncolytics 2016

Similar Publications